Q2 2021 13F Holders as of 6/30/2021
-
Type / Class
-
Equity / Common Stock, $0.0001 par value per share
-
Shares outstanding
-
40.6M
-
Number of holders
-
77
-
Total 13F shares, excl. options
-
12.9M
-
Shares change
-
-309K
-
Total reported value, excl. options
-
$547M
-
Value change
-
-$44.3M
-
Number of buys
-
49
-
Number of sells
-
-33
-
Price
-
$42.47
Significant Holders of Keros Therapeutics, Inc. - Common Stock, $0.0001 par value per share (KROS) as of Q2 2021
95 filings reported holding KROS - Keros Therapeutics, Inc. - Common Stock, $0.0001 par value per share as of Q2 2021.
Keros Therapeutics, Inc. - Common Stock, $0.0001 par value per share (KROS) has 77 institutional shareholders that have filed 13F forms with the Securities Exchange Commission (SEC).
These institutions hold a total of 12.9M shares
of 40.6M outstanding shares and own 31.7% of the company stock.
Largest 10 shareholders include FMR LLC (3.49M shares), ORBIMED ADVISORS LLC (1.68M shares), Consonance Capital Management LP (888K shares), ALKEON CAPITAL MANAGEMENT LLC (703K shares), STATE STREET CORP (679K shares), VANGUARD GROUP INC (668K shares), Nantahala Capital Management, LLC (599K shares), EVENTIDE ASSET MANAGEMENT, LLC (427K shares), Point72 Asset Management, L.P. (403K shares), and FRANKLIN RESOURCES INC (395K shares).
This table shows the top 77 institutional shareholders of the company equity. This data is sourced directly from the SEC via 13F filings.
| Investor |
Option |
Weight % |
Change % |
Value $ |
* Price $ |
Shares |
Share Change |
Activity |
Report Period |
* Reported Price is the price of the security as of the portfolio date. This value is significant in that it is the last known price at which the security was still held.
An asterisk sign (*) next to the price indicates that the price is likely invalid.